Drug manufacturer’s AstraZeneca and the federal government continue to joust in court as they await a crucial decision in the company’s 340B contract pharmacy lawsuit.
The two sides on Friday filed a joint status report in Astra’s lawsuit to
…
Articles by : Tom Mirga, Editor at Large
U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
In a Nov. 11 joint
…
Kaiser Health News (KHN), a nonprofit health care news organization whose stories are widely and freely republished and rebroadcast, released an in-depth article and news video today about the 340B program and the fight over 340B contract pharmacy.
According to
…
Drug manufacturer Eli Lilly late yesterday filed notice that it is appealing a federal district judge’s Oct. 29 ruling partially in Lilly’s favor and partially for the federal government on the legality of Lilly’s denials of 340B ceiling prices when
…
In a major organizational change, the U.S. Health Resources and Services Administration (HRSA) has redefined the job of Director of the Office of Pharmacy Affairs (OPA), the HRSA unit that runs the 340B program.
For the first time in 340B
…
The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next
…
A hospital group says two federal district judges got it right, but one got it wrong, on whether drug manufacturers are legally bound to provide 340B drug discounts for drugs dispensed at contract pharmacies.
In a Nov. 6 statement, 340B
…
A new research letter published in JAMA Internal Medicine found substantial variation among 17 “top-performing” hospitals—14 of them enrolled in 340B—in what they charge commercial insurers for clinician-administered drugs.
Meanwhile, new research published in Journal of Healthcare Quality found that
…
A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,
…Breaking News
Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits
A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease.
U.S. Chief District Judge
…